Shanghai MicuRx Pharmaceutical Co., Ltd.

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

166

Website

www.micurxchina.com

Country

China

Exchange

Shanghai

Founded 2007

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria.

Its portfolio also includes MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria, MRX-5 for multidrug-resistant gram-negative bacteria, MRX-7 for multidrug-resistant gram-positive bacteria, MRX-15 and MRX-17 to treat kidney disease, MRX-18 for the treatment of COVID-19, and MRX-23 for the treatment of tumour. Founded in 2007, the company is based in Shanghai, China.

Key Stats

52-Week Range

¥4.09¥10.31

Beta0.39

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.31

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.